FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 384 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... September 9, 2022 7 ways we’ve influenced progress in lung cancer November 1, 2022 FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma September 26, 2023 Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 Load more HOT NEWS E-cigarettes: what we know and what we don’t Witness the Moment of Absolute Triumph as Baltimore Woman Is Finally... Doctors Think Woman Has A Brain Tumor, But Then They Open... Having a Heart Attack May Make Breast Cancer Grow Faster
